苏格兰-话题@MedSci

#苏格兰#

16篇内容 | 1065人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1769761, encodeId=73c11e6976129, content=<a href='/topic/show?id=c7df8e00304' target=_blank style='color:#2F92EE;'>#苏格兰#</a>, objectTitle=Lancet Respir Med：苏格兰25700万人接种新冠疫苗后的住院和死亡风险, objectType=article, longId=220467, objectId=9ca022046e18, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ca022046e18, replyNumber=0, likeNumber=82, createdTime=2022-06-19, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ca022046e18, moduleTitle=Lancet Respir Med：苏格兰25700万人接种新冠疫苗后的住院和死亡风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ca022046e18)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1769759, encodeId=c8781e6975965, content=<a href='/topic/show?id=c7df8e00304' target=_blank style='color:#2F92EE;'>#苏格兰#</a>, objectTitle=苏格兰药物联盟 (SMC) 批准Cabometyx/Opdivo组合治疗晚期肾癌患者, objectType=article, longId=218568, objectId=c15d218568ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c15d218568ba, replyNumber=0, likeNumber=86, createdTime=2021-10-15, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c15d218568ba, moduleTitle=苏格兰药物联盟 (SMC) 批准Cabometyx/Opdivo组合治疗晚期肾癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c15d218568ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1769757, encodeId=ce5e1e69757e6, content=<a href='/topic/show?id=c7df8e00304' target=_blank style='color:#2F92EE;'>#苏格兰#</a>, objectTitle=柳叶刀：苏格兰大规模接种首剂COVID-19疫苗后，COVID-19住院人数减少, objectType=article, longId=210496, objectId=fc7d210496c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc7d210496c0, replyNumber=0, likeNumber=86, createdTime=2021-06-03, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc7d210496c0, moduleTitle=柳叶刀：苏格兰大规模接种首剂COVID-19疫苗后，COVID-19住院人数减少, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc7d210496c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1769762, encodeId=47301e69762e5, content=<a href='/topic/show?id=c7df8e00304' target=_blank style='color:#2F92EE;'>#苏格兰#</a>, objectTitle=Lancet Respir Med ：苏格兰5～17岁哮喘儿童COVID-19住院风险, objectType=article, longId=221437, objectId=823422143e35, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=823422143e35, replyNumber=0, likeNumber=96, createdTime=2022-07-22, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=823422143e35, moduleTitle=Lancet Respir Med ：苏格兰5～17岁哮喘儿童COVID-19住院风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=823422143e35)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1769760, encodeId=af6c1e69760ad, content=<a href='/topic/show?id=c7df8e00304' target=_blank style='color:#2F92EE;'>#苏格兰#</a>, objectTitle=苏格兰药物联盟 (SMC)批准Ponvory (ponsimod)治疗复发性多发性硬化症（内容较少，麻烦补充，谢谢）, objectType=article, longId=220349, objectId=a6392203493e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a6392203493e, replyNumber=0, likeNumber=82, createdTime=2022-07-06, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a6392203493e, moduleTitle=苏格兰药物联盟 (SMC)批准Ponvory (ponsimod)治疗复发性多发性硬化症（内容较少，麻烦补充，谢谢）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a6392203493e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1769756, encodeId=80241e6975661, content=<a href='/topic/show?id=c7df8e00304' target=_blank style='color:#2F92EE;'>#苏格兰#</a>, objectTitle=Br J Cancer：新冠肺炎对苏格兰地区全身抗癌药物治疗的影响, objectType=article, longId=206795, objectId=1159206e95f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1159206e95f8, replyNumber=0, likeNumber=77, createdTime=2021-11-01, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1159206e95f8, moduleTitle=Br J Cancer：新冠肺炎对苏格兰地区全身抗癌药物治疗的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1159206e95f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1769758, encodeId=61d91e69758b4, content=<a href='/topic/show?id=c7df8e00304' target=_blank style='color:#2F92EE;'>#苏格兰#</a>, objectTitle=Lancet：英国苏格兰数据显示AZ新冠疫苗似乎不如辉瑞新冠疫苗有效, objectType=article, longId=212749, objectId=e8a8212e49c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8a8212e49c1, replyNumber=0, likeNumber=84, createdTime=2021-08-09, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8a8212e49c1, moduleTitle=Lancet：英国苏格兰数据显示AZ新冠疫苗似乎不如辉瑞新冠疫苗有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e8a8212e49c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1769755, encodeId=75e51e6975507, content=<a href='/topic/show?id=c7df8e00304' target=_blank style='color:#2F92EE;'>#苏格兰#</a>, objectTitle=Diabetologia：1型糖尿病患者50岁前死亡的时间趋势-基于苏格兰2004-2017年的全国分析, objectType=article, longId=203955, objectId=77da2039552e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=77da2039552e, replyNumber=0, likeNumber=73, createdTime=2021-07-02, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=77da2039552e, moduleTitle=Diabetologia：1型糖尿病患者50岁前死亡的时间趋势-基于苏格兰2004-2017年的全国分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=77da2039552e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1769754, encodeId=2e5c1e69754da, content=<a href='/topic/show?id=c7df8e00304' target=_blank style='color:#2F92EE;'>#苏格兰#</a>, objectTitle=苏格兰医药联盟积极推荐Darzalex作为多发性骨髓瘤的二线治疗方案, objectType=article, longId=175081, objectId=1ce51e50810d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ce51e50810d, replyNumber=0, likeNumber=77, createdTime=2019-12-05, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ce51e50810d, moduleTitle=苏格兰医药联盟积极推荐Darzalex作为多发性骨髓瘤的二线治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ce51e50810d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1769753, encodeId=d1ed1e69753bf, content=<a href='/topic/show?id=c7df8e00304' target=_blank style='color:#2F92EE;'>#苏格兰#</a>, objectTitle=苏格兰SMC批准礼来的CDK4/6抑制剂abemaciclib，用于治疗晚期或转移性乳腺癌, objectType=article, longId=166117, objectId=2c7916611e50, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c7916611e50, replyNumber=0, likeNumber=97, createdTime=2020-01-21, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c7916611e50, moduleTitle=苏格兰SMC批准礼来的CDK4/6抑制剂abemaciclib，用于治疗晚期或转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c7916611e50)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1769752, encodeId=b8821e697523d, content=<a href='/topic/show?id=c7df8e00304' target=_blank style='color:#2F92EE;'>#苏格兰#</a>, objectTitle=DIABETOLOGIA：2006年至2015年期间苏格兰2型糖尿病患者急性心肌梗死，心绞痛和冠状动脉血运重建的发病率和病死率趋势, objectType=article, longId=163572, objectId=3dab1635e268, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3dab1635e268, replyNumber=0, likeNumber=77, createdTime=2019-05-20, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3dab1635e268, moduleTitle=DIABETOLOGIA：2006年至2015年期间苏格兰2型糖尿病患者急性心肌梗死，心绞痛和冠状动脉血运重建的发病率和病死率趋势, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3dab1635e268)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1769751, encodeId=d9fd1e6975111, content=<a href='/topic/show?id=c7df8e00304' target=_blank style='color:#2F92EE;'>#苏格兰#</a>, objectTitle=四种新药获准用于苏格兰国民健康保险制度, objectType=article, longId=146661, objectId=431b14666146, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=431b14666146, replyNumber=0, likeNumber=60, createdTime=2019-03-30, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=431b14666146, moduleTitle=四种新药获准用于苏格兰国民健康保险制度, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=431b14666146)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1769750, encodeId=39e81e6975031, content=<a href='/topic/show?id=c7df8e00304' target=_blank style='color:#2F92EE;'>#苏格兰#</a>, objectTitle=苏格兰药物联盟批准Kyntheum用于中重度斑块状银屑病患者, objectType=article, longId=138000, objectId=6853138000b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6853138000b3, replyNumber=0, likeNumber=83, createdTime=2018-05-19, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6853138000b3, moduleTitle=苏格兰药物联盟批准Kyntheum用于中重度斑块状银屑病患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6853138000b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1769749, encodeId=81031e6974956, content=<a href='/topic/show?id=c7df8e00304' target=_blank style='color:#2F92EE;'>#苏格兰#</a>, objectTitle=苏格兰的Synpromics扩大与UCL在基因治疗方面的合作, objectType=article, longId=127951, objectId=99f912e9518b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=99f912e9518b, replyNumber=0, likeNumber=80, createdTime=2018-09-07, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=99f912e9518b, moduleTitle=苏格兰的Synpromics扩大与UCL在基因治疗方面的合作, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=99f912e9518b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1769748, encodeId=d41e1e69748bb, content=<a href='/topic/show?id=c7df8e00304' target=_blank style='color:#2F92EE;'>#苏格兰#</a>, objectTitle=肺癌患者福音！苏格兰医药协会批准两款NSCLC新药, objectType=article, longId=73097, objectId=43abe309703, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43abe309703, replyNumber=0, likeNumber=76, createdTime=2016-12-24, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43abe309703, moduleTitle=肺癌患者福音！苏格兰医药协会批准两款NSCLC新药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43abe309703)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1769747, encodeId=37d71e697479a, content=<a href='/topic/show?id=c7df8e00304' target=_blank style='color:#2F92EE;'>#苏格兰#</a>, objectTitle=苏格兰独立，当地科研是喜是忧？, objectType=article, longId=40256, objectId=94b440256e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94b440256e2, replyNumber=0, likeNumber=83, createdTime=2014-10-19, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94b440256e2, moduleTitle=苏格兰独立，当地科研是喜是忧？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94b440256e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

苏格兰

2020-05-29

quxin068 (审核中...)

前往app查看评论内容

#苏格兰#

Lancet Respir Med：苏格兰25700万人接种新冠疫苗后的住院和死亡风险

2022-06-19

quxin068 (审核中...)

前往app查看评论内容

#苏格兰#

苏格兰药物联盟 (SMC) 批准Cabometyx/Opdivo组合治疗晚期肾癌患者

2021-10-15

quxin068 (审核中...)

前往app查看评论内容

#苏格兰#

柳叶刀：苏格兰大规模接种首剂COVID-19疫苗后，COVID-19住院人数减少

2021-06-03

quxin068 (审核中...)

前往app查看评论内容

#苏格兰#

Lancet Respir Med ：苏格兰5～17岁哮喘儿童COVID-19住院风险

2022-07-22

quxin068 (审核中...)

前往app查看评论内容

#苏格兰#

苏格兰药物联盟 (SMC)批准Ponvory (ponsimod)治疗复发性多发性硬化症（内容较少，麻烦补充，谢谢）

2022-07-06

quxin068 (审核中...)

前往app查看评论内容

#苏格兰#

Br J Cancer：新冠肺炎对苏格兰地区全身抗癌药物治疗的影响

2021-11-01

quxin068 (审核中...)

前往app查看评论内容

#苏格兰#

Lancet：英国苏格兰数据显示AZ新冠疫苗似乎不如辉瑞新冠疫苗有效

2021-08-09

quxin068 (审核中...)

前往app查看评论内容

#苏格兰#

Diabetologia：1型糖尿病患者50岁前死亡的时间趋势-基于苏格兰2004-2017年的全国分析

2021-07-02

quxin068 (审核中...)

前往app查看评论内容

#苏格兰#

苏格兰医药联盟积极推荐Darzalex作为多发性骨髓瘤的二线治疗方案

2019-12-05

quxin068 (审核中...)

前往app查看评论内容

#苏格兰#

苏格兰SMC批准礼来的CDK4/6抑制剂abemaciclib，用于治疗晚期或转移性乳腺癌

2020-01-21

quxin068 (审核中...)

前往app查看评论内容

#苏格兰#

DIABETOLOGIA：2006年至2015年期间苏格兰2型糖尿病患者急性心肌梗死，心绞痛和冠状动脉血运重建的发病率和病死率趋势

2019-05-20

quxin068 (审核中...)

前往app查看评论内容

#苏格兰#

四种新药获准用于苏格兰国民健康保险制度

2019-03-30

quxin068 (审核中...)

前往app查看评论内容

#苏格兰#

苏格兰药物联盟批准Kyntheum用于中重度斑块状银屑病患者

2018-05-19

quxin068 (审核中...)

前往app查看评论内容

#苏格兰#

苏格兰的Synpromics扩大与UCL在基因治疗方面的合作

2018-09-07

quxin068 (审核中...)

前往app查看评论内容

#苏格兰#

肺癌患者福音！苏格兰医药协会批准两款NSCLC新药

2016-12-24

quxin068 (审核中...)

前往app查看评论内容

#苏格兰#

苏格兰独立，当地科研是喜是忧？

2014-10-19

科室
- - 订阅+
  - 更多科室
工具
服务